Litigation Details for HORIZON THERAPEUTICS, LLC v. LUPIN LTD. (D.N.J. 2017)
HORIZON THERAPEUTICS, LLC v. LUPIN LTD. (D.N.J. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-08-08 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-07-10 |
| Cause | 35:271 Patent Infringement | Assigned To | Kevin McNulty |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Patents | 8,642,012; 9,561,197 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in HORIZON THERAPEUTICS, LLC v. LUPIN LTD.
Details for HORIZON THERAPEUTICS, LLC v. LUPIN LTD. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-08-08 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation Summary and IP Analysis: HORIZON THERAPEUTICS, LLC v. LUPIN LTD. (2:17-cv-05900)
Horizon Therapeutics sued Lupin in 2017 in the US District Court in the District of New Jersey for asserted patent infringement tied to Lupin’s FDA-filed generic/ANDA product associated with Horizon’s commercial drug. The case is docketed as 2:17-cv-05900 and is part of the Paragraph IV-style patent litigation track commonly triggered by ANDA submissions.
Case caption: Horizon Therapeutics, LLC v. Lupin Ltd.
Docket: 2:17-cv-05900
Filed: 2017 (within the 2017 term of the case record)
What patents were asserted in Horizon Therapeutics v. Lupin (2:17-cv-05900)?
Answer: This court record cannot be completed from the information provided in the prompt, so the asserted patent numbers, claims, and expiration dates cannot be stated.
What is typically included in the Horizon v. Lupin pleadings?
- List of asserted Orange Book patents (drug substance, formulation, and/or method-of-use)
- Claim-by-claim infringement allegations
- Active-ingredient mapping to ANDA labeling
- Defenses including invalidity and non-infringement
Which Horizon patent estates are most commonly targeted in ANDA litigations?
For Horizon, the litigation universe typically includes:
- Small-molecule branded products with Orange Book coverage
- Formulation and use patents for dosing regimens and label-anchored therapies
No asserted-patent identifiers are available here, so no mapping to Horizon’s specific estates can be produced.
What does the infringement theory look like for a Paragraph IV ANDA case like 2:17-cv-05900?
Answer: For ANDA generic cases brought by brand owners, the infringement theory usually tracks the “I(i) kit” approach in which the ANDA label and formulation describe the product the generic seeks to market, and asserted claims are tested against those proposed product attributes.
Typical infringement elements courts evaluate
- Whether the ANDA product falls within formulation claim parameters (excipients, particle size, release profile, salt form, pH, stability-related features)
- Whether the ANDA label falls within method-of-use claims (indication, patient population, dosing schedule, co-administration)
- Whether the generic’s manufacturing method is relevant (rare for ANDA unless method patents are asserted)
Typical generic non-infringement arguments
- Differences in formulation parameters
- Design-around of the claimed method-of-use instructions
- Substitution of a different salt/polymorph form
- Lack of “directed” conduct under induced infringement theories
Typical invalidity arguments
- Anticipation or obviousness based on prior art publications or patents
- Written description and enablement challenges
- Indefiniteness for claim terms
- Obviousness combining references
What is the procedural timeline for Horizon v. Lupin in 2:17-cv-05900?
Answer: The precise timeline cannot be reproduced without the court docket details, orders, and filing dates.
Information that controls the timeline in these cases
- Complaint filing date and service
- Answer and any amended pleadings
- Markman schedule
- Expert discovery cutoffs
- Claim construction order dates
- Summary judgment motions
- Trial (if not settled)
- Dismissal/stipulation entry dates
How strong are Horizon’s patents in this litigation?
Answer: Patent strength cannot be assessed because the asserted patent set, claim coverage, and cited references are not provided.
What “strength” analysis usually requires
- Independent-claim types asserted (composition vs. method vs. device)
- Whether Horizon asserted “core” patents with commercial relevance
- Whether generic challenged validity with specific art
- Claim construction outcomes that narrowed scope
Without the asserted patents and claim details, no strength score or litigation risk profile is deliverable.
What is the litigation posture and outcome (settlement, dismissal, judgment) for 2:17-cv-05900?
Answer: The case outcome cannot be stated from the prompt. Settlement status, court judgment, and remaining patents cannot be reported without docket and order records.
Common outcomes in ANDA patent cases
- Case dismissed after a settlement
- Judgment after claim construction and summary judgment
- Partial settlement with remaining asserted patents
- Voluntary dismissal or stipulation tied to FDA approval timing
What Paragraph IV and FDA exclusivity events affected this case?
Answer: Specific FDA events for the ANDA associated with 2:17-cv-05900 cannot be provided because no drug name, ANDA number, or Orange Book listing is stated.
What an exclusivity timeline usually looks like
- Orange Book listing trigger date
- 30-month stay start and expiration
- Settlement tied to a launch date
- Design-around approval if relevant
No ANDA identifiers are available to anchor the timeline.
Which companies are involved beyond Horizon and Lupin in 2:17-cv-05900?
Answer: Co-defendants, manufacturing partners, and FDA-related parties cannot be identified from the prompt.
Typical parties
- Brand owner: Horizon Therapeutics
- Generic ANDA filer: Lupin Ltd.
- Additional defendants (common): Lupin’s US entity, contract manufacturers, distribution entities
No such entities can be listed here.
What generic entry risks existed for Lupin at the time of filing (2017)?
Answer: Entry risk depends on (1) the asserted patents, (2) the likelihood of invalidity and non-infringement, and (3) the controlling FDA stay/exclusivity window. None of those inputs are provided.
Risk factors that typically drive the outcome
- Claim construction narrowing
- Prior art strength against obviousness
- Whether the patent is formulation-level or method-of-use
- Whether the ANDA design avoids claimed features
How does this case compare with other Horizon v. generic defendant litigations?
Answer: Comparison requires asserted patent sets, adjudicative outcomes, and settlement terms from this case and comparable matters. Those inputs are not present.
Key Takeaways
- Horizon Therapeutics, LLC v. Lupin Ltd. is docketed as 2:17-cv-05900 and filed in 2017.
- A complete litigation summary with asserted patents, procedural milestones, and outcome cannot be produced from the information supplied in the prompt.
- Litigation risk and strength analysis require the asserted patent numbers, claims, and docket orders, which are not available here.
FAQs
-
What court handled Horizon Therapeutics v. Lupin (2:17-cv-05900)?
The prompt identifies the case by docket number only; the specific court division and judge are not provided. -
Was the case decided on claim construction or summary judgment?
No procedural decision data is provided in the prompt. -
Did Lupin launch “at risk” or after a settlement in 2:17-cv-05900?
No settlement or launch timing is provided. -
Which Orange Book patents does Horizon typically assert in Lupin ANDA litigations?
The asserted patents for this case are not provided, so a case-specific list cannot be compiled. -
What FDA stay period governed this litigation’s timing?
ANDA number and FDA stay dates are not provided.
References
No sources are provided or citable from the prompt content.
More… ↓
